Kintai Therapeutics

Biotechnology ResearchMassachusetts, United States51-200 Employees

Kintai Therapeutics concentrates on decoding the enteric signaling network and its systemic effects to address disease and restore patient health. Its Precision Enteric Medicine platform builds on the interconnected biology of the microbiome, gut immune system, and enteric nervous system to translate insights into medicines. The company has developed a pipeline spanning multiple therapeutic areas, including oncology, neurology, and immunology. Founded in 2016 by Flagship Labs, the innovation foundry of Flagship Pioneering, Kintai is based in Cambridge, Massachusetts. As part of its governance, John Mendlein was appointed chairman of the board in January 2020.

Sign up for free to view info

Email Format Employee directory